AWKNF

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Awakn Life Sciences (AWKNF - Research Report), with a price target of $10.00. The company's shares closed yesterday at $0.39.Trucchio covers the Healthcare sector, focusing on stocks such as Immunocore Holdings, Altimmune, and Oncolytics Biotech. According to TipRanks, Trucchio has an average return of -14.8% and a 33.80% success rate on recommended stocks. Currently, the analyst consensus on Awakn Life Sciences is a Moderate Buy with an average price target of $10.00.See the top stocks recommended by analysts >>The company has a one-year high of $2.71 and a one-year low of $0.26.
https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-awakn-life-sciences-awknf?utm_source=advfn.com&utm_medium=referral